Lupus erythematosus - Lupus Eritematoso
☆ Nos resultados de Stiftung Warentest de Alemaña de 2022, a satisfacción dos consumidores con ModelDerm foi só lixeiramente inferior á das consultas de telemedicina pagas.
Aparece como un eritema lixeiramente violáceo.
A erupción da bolboreta que adoita aparecer na cara.
relevance score : -100.0%
ReferencesIdentificar e clasificar o cutaneous lupus erythematosus (CLE) presenta retos diagnósticos, ao distinguilo do systemic lupus erythematosus con afectación cutánea. Estudos recentes arrochan luz sobre os factores xenéticos, ambientais e inmunolóxicos que subxacen ao CLE. A indución de fármacos xurdiu especificamente como un dos desencadenantes máis importantes do CLE. O tratamento implica terapias tópicas e sistémicas, incluíndo biolóxicos prometedores (belimumab, rituximab, ustekinumab, anifrolumab, BIIB059), cunha eficacia demostrada nos ensaios clínicos.
Diagnostic challenges exist in better defining cutaneous lupus erythematosus (CLE) as an independent disease distinct from systemic lupus erythematosus with cutaneous features and further classifying CLE based on clinical, histological, and laboratory features. Recent mechanistic studies revealed more genetic variations, environmental triggers, and immunologic dysfunctions that are associated with CLE. Drug induction specifically has emerged as one of the most important triggers for CLE. Treatment options include topical agents and systemic therapies, including newer biologics such as belimumab, rituximab, ustekinumab, anifrolumab, and BIIB059 that have shown good clinical efficacy in trials.
Diagnostic challenges exist in better defining cutaneous lupus erythematosus (CLE) as an independent disease distinct from systemic lupus erythematosus with cutaneous features and further classifying CLE based on clinical, histological, and laboratory features. Recent mechanistic studies revealed more genetic variations, environmental triggers, and immunologic dysfunctions that are associated with CLE. Drug induction specifically has emerged as one of the most important triggers for CLE. Treatment options include topical agents and systemic therapies, including newer biologics such as belimumab, rituximab, ustekinumab, anifrolumab, and BIIB059 that have shown good clinical efficacy in trials.
Cutaneous lupus erythematosus (CLE) abarca varios problemas da pel, algúns dos cales poden estar relacionados con problemas de saúde máis amplos. Está clasificado en diferentes tipos, como acute CLE (ACLE), sub‑acute CLE (SCLE) e chronic CLE (CCLE). CCLE comprende discoid lupus erythematosus (DLE), LE profundus (LEP), chilblain cutaneous lupus e lupus tumidus.
Cutaneous lupus erythematosus (CLE) encompasses a wide range of dermatologic manifestations, which may or may not be associated with the development of systemic disease. Cutaneous lupus is divided into several sub-types, including acute CLE (ACLE), sub-acute CLE (SCLE) and chronic CLE (CCLE). CCLE includes discoid lupus erythematosus (DLE), LE profundus (LEP), chilblain cutaneous lupus and lupus tumidus.
Cutaneous lupus erythematosus (CLE) encompasses a wide range of dermatologic manifestations, which may or may not be associated with the development of systemic disease. Cutaneous lupus is divided into several sub-types, including acute CLE (ACLE), sub-acute CLE (SCLE) and chronic CLE (CCLE). CCLE includes discoid lupus erythematosus (DLE), LE profundus (LEP), chilblain cutaneous lupus and lupus tumidus.
Lupus erythematosus é un grupo de enfermidades autoinmunes que poden afectar distintas partes do corpo. Algúns tipos, como systemic lupus erythematosus (SLE), afectan varios órganos, mentres que outros, como cutaneous lupus erythematosus (CLE), afectan principalmente a pel. Clasificamos os diferentes tipos de CLE en función dunha combinación de signos clínicos, exame de tecidos e análises de sangue, pero existe gran variación entre os individuos. Os problemas cutáneos adoitan desenvolverse debido a factores como a exposición á luz solar, o tabaquismo ou certos medicamentos.
Lupus erythematosus comprises a spectrum of autoimmune diseases that may affect various organs (systemic lupus erythematosus [SLE]) or the skin only (cutaneous lupus erythematosus [CLE]). Typical combinations of clinical, histological and serological findings define clinical subtypes of CLE, yet there is high interindividual variation. Skin lesions arise in the course of triggers such as ultraviolet (UV) light exposure, smoking or drugs
Lupus erythematosus comprises a spectrum of autoimmune diseases that may affect various organs (systemic lupus erythematosus [SLE]) or the skin only (cutaneous lupus erythematosus [CLE]). Typical combinations of clinical, histological and serological findings define clinical subtypes of CLE, yet there is high interindividual variation. Skin lesions arise in the course of triggers such as ultraviolet (UV) light exposure, smoking or drugs
A causa do lupus eritematoso (Lupus erythematosus) non está clara. Entre os xemelgos idénticos, se un está afectado existe un 24 % de probabilidade de que o outro tamén o estea. Tamén se cree que as hormonas sexuais femininas, a exposición ao sol, o tabaquismo, a deficiencia de vitamina D e certas infeccións aumentan o risco.
Os tratamentos poden incluír NSAIDs (AINE), corticosteroids (corticoides), inmunosupresores, hydroxychloroquine (hidroxicloroquina) e methotrexate (metotrexato). Aínda que os corticosteroids (corticosteroides) son eficaces, o uso a longo prazo produce efectos secundarios.